Dogwood Therapeutics, Inc.
DWTXDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 12, 2026
8dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
DWTX Earnings Report
EPS Est: $-0.13 | FQ end 2026-06
How DWTX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Halneuron | Phase 2 | Chemotherapy Induced Neuropathic Pain | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Dogwood Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Dogwood Therapeutics, Inc.'s (DWTX) pipeline across Phase 2. Its lead program is Halneuron (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Dogwood Therapeutics, Inc.'s next FDA catalyst?→
Dogwood Therapeutics, Inc.'s (DWTX) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DWTX biotech catalysts?→
Add DWTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Dogwood Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.